Format

Send to

Choose Destination
See comment in PubMed Commons below
Cancer Invest. 2009 Oct;27(8):851-6. doi: 10.1080/07357900902744528.

Increased hemoglobin associated with VEGF inhibitors in advanced renal cell carcinoma.

Author information

1
Stanford University School of Medicine, California 94305, USA. laurenhs@stanford.edu

Abstract

We retrospectively analyzed whether increased hemoglobin is a surrogate biomarker of efficacy for vascular endothelial growth factor (VEGF) inhibitors in advanced renal cell carcinoma (RCC) patients. Twelve patients were identified who had received bevacizumab alone or as combination therapy. Eleven patients experienced a rise in hemoglobin. Median change was 1.6 g/dL (0-4.0). Degree of peak increase correlated with longer progression-free survival (PFS) in metastatic patients: increase of < 15% yielded a 3.1-month median PFS compared to 8.2 months with rises > 15%. This study identifies increased hemoglobin as a possible consequence of VEGF inhibitors. The correlation with longer PFS suggests that rise in hemoglobin may be a surrogate biomarker of efficacy.

PMID:
19603304
DOI:
10.1080/07357900902744528
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center